Stocks
Innate Immunotherapeutics LtdIIL
NASDAQHealthcareBiotechnology
A biotechnology company focused on developing immune‑modulating therapies for autoimmune diseases. Its primary asset, MIS416, has been studied as a potential treatment for progressive multiple sclerosis by targeting innate immune pathways. Investors have followed the company largely for the clinical...
52W Range: $0.03 – $0.05
Congressional Interest in Innate Immunotherapeutics Ltd (IIL)
1 member of Congress has disclosed 2 trades in Innate Immunotherapeutics Ltd (IIL), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
2
Sells
0
Who in Congress Is Trading IIL?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-02-03 | K. Michael Conaway | buy | $1K – $15K |
| 2017-01-26 | K. Michael Conaway | buy | $1K – $15K |